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Over the last four decades the HIV pandemic and advances in
medical treatments that also cause immunosuppression have
produced an ever-growing cohort of individuals susceptible to
opportunistic pathogens. Of these, AIDS patients are particu-
larly vulnerable to infection by the encapsulated yeast Crypto-
coccus neoformans. Most commonly found in the environment
in purine-rich bird guano, C. neoformans experiences a drastic
change in nutrient availability during host infection, ultimately
disseminating to colonize the purine-poor central nervous sys-
tem. Investigating the consequences of this challenge, we have
characterizedC. neoformansGMP synthase, the second enzyme
in the guanylate branchofdenovopurine biosynthesis.We show
that in the absence of GMP synthase, C. neoformans becomes a
guanine auxotroph, the production of key virulence factors is
compromised, and the ability to infect nematodes and mice is
abolished. Activity assays performedusing recombinant protein
unveiled differences in substrate binding between theC. neofor-
mans and human enzymes, with structural insights into these
kinetic differences acquired via homology modeling. Collec-
tively, these data highlight the potential of GMP synthase to be
exploited in the development of new therapeutic agents for the
treatment of disseminated, life-threatening fungal infections.
In the past four decades there has been a dramatic escalation
in the number of immunocompromised individuals (1).
Although many of these are due to advances in immunosup-
pressive and chemotherapeutic technologies, the largest cohort
is a direct result of the AIDS pandemic. Foreshadowed in 1981
with the occurrence of opportunistic Pneumocystis or human
herpesvirus 8 infections in previously healthy individuals in Los
Angeles (2, 3), AIDS and the lentivirus causing the disease soon
gained broad public awareness (4–6).With the advent of com-
mercial blood testing, national blood bank screening programs
were commenced in an effort to slow the spread of this emerg-
ing pandemic (7), and in 1987 the first treatment, zidovudine,
marked what was thought to be an end to the crisis (8, 9). It was
not, aswas hoped, amiracle drug; the spread ofAIDS continued
across the globe and is now believed to have infected over 70
million people and killed 55 million to date (10).
Since the discovery of the very first patients identified with
Pneumocystis pneumonia, opportunistic fungal pathogens have
been tightly linked with the AIDS pandemic. One of the key
fungi often encountered in this context is Cryptococcus neofor-
mans, a basidiomycete yeast responsible for cryptococcosis and
a major cause of AIDS-related mortality (11). Most commonly
found associated with purine-rich bird guano, spores or desic-
cated yeast cells from this environmental niche are inhaled into
the lungs where, in an immunocompromised individual, the
fungus can disseminate to the purine-poor central nervous sys-
tem to cause meningoencephalitis.
The fundamental treatment for cryptococcosis has not
changed significantly in over twodecades and consists of induc-
tion with amphotericin B and flucytosine followed by consoli-
dation and maintenance phases employing fluconazole (12–
16). Each of these therapeutic agents exploit an aspect of fungal
physiology that differs from the human host: the presence of
ergosterol rather than cholesterol in the cell membrane, the
existence of the pyrimidine salvage enzyme cytosine deami-
nase, or changes in the sterol biosynthetic pathway, respec-
tively. Even so, each of these agents still cause side effects,
epitomized by the compromised renal function typical of
amphotericin B use.
The similarity in physiology between human host and fungal
pathogen means there are few gross differences that can be
easily targeted via rational drug design. However, differences
such as slight changes in the active site of enzymes in a highly
conserved essential pathway may be exploited, as typified by
fluconazole. One such potential target is de novo purine biosyn-
thesis, the pathway in which the process of rational drug design
was pioneered (17–19). Proliferating cells require vast quanti-
ties of ATP and GTP to meet the demands of replication, tran-
scription, and energy metabolism. Purine biosynthesis is there-
fore essential in rapidly dividing immune cells, cancers, or
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infectingmicrobes. The pathway is already a target for antican-
cer drugs (such as mercaptopurine and lometrexol) and immu-
nosuppressants (such as mycophenolic acid) (20–24). How-
ever, the investigation of purine metabolism as an antifungal
target has been limited (25–27).
Purine metabolism is of particular interest in C. neoformans
because of the gross disparity in purine concentrations in bird
guano compared with the central nervous system of the
infected human host (28–30). The importance of de novo bio-
synthesis rather than scavenging while the fungus infects this
purine-poor environmentwas highlighted by the discovery that
IMP dehydrogenase, catalyst of the rate-limiting and first com-
mitted step in the de novoGTP biosynthesis pathway, is essen-
tial for C. neoformans virulence in a murine model. Impor-
tantly, structural studies of this enzyme revealed potentially
exploitable characteristics of the fungal enzymenot sharedwith
the human isoforms (25).
IMP dehydrogenase is not the only enzyme in de novo GTP
biosynthesis that has potential as an antimycotic target. Follow-
ing IMP dehydrogenase in the guanylate branch of de novo
purine biosynthesis is GMP synthase (E.C. 6.3.5.2). Originally
identified in ground rabbit bone marrow (31) and pigeon liver
(32), the key work that underpins our current understanding of
GMP synthase was performed in Escherichia coli (33, 34), and
this system continues to be the source for a detailed biochemi-
cal understanding of the activity of the enzyme (35–37).
GMP synthase is a monofunctional enzyme in all organisms
studied so far, with two catalytic modules working in concert
to ensure efficient amination of xanthine monophosphate
(XMP)2 to GMP. The magnesium-dependent ATP pyrophos-
phatase (ATP-PPase) domain reversibly adenylates XMP to
form a covalent O2-adenyl-XMP intermediate; this activates
the C2 carbon of XMP for attack by the amide side chain of
glutamine, liberated by the class I glutamine amidotransferase
(GATase) domain (33, 34, 38).
Crystal structure determination of E. coli GMP synthase
identified the enzyme as having three distinct domains: the
N-terminal ATP-PPase domain, the GATase domain, and a
C-terminal dimerization domain, and supported early sedi-
mentation velocity experiments indicating E. coli GMP syn-
thase forms a homodimer (34, 39).GMP synthase structures are
now available for other bacterium (Coxiella burnetii (40)
and Thermus thermophiles (PDB codes 2YWB and 2YWC)),
archaea (Pyrococcus horikoshii (41)), and two eukaryotes (Plas-
modium falciparum (42),Homo sapiens (43)); all contain ATP-
PPase, GATase, and dimerization domains.
In contrast, few studies of GMP synthase have been per-
formed in fungi. The GMP synthase gene has been identified
and mutated in Saccharomyces cerevisiae, Candida albicans,
and Aspergillus fumigatus; as expected, these mutants were all
guanine auxotrophs (26, 44–46). Furthermore, the GMP syn-
thasemutants ofC. albicans andA. fumigatuswere avirulent in
murine infection models (26). No kinetics or structural studies
of fungal GMP synthases are available.
Here, we describe the characterization of GMP synthase
from C. neoformans, showing the potential of the enzyme as a
broad spectrum antifungal target. Using genetic techniques, we
demonstrate that GMP synthase is required for C. neoformans
virulence factor production and successful infection of the host.
With the aid of biochemical analyses and structural modeling,
we identify key functional differences between GMP synthase
from C. neoformans and humans, thereby delineating its suit-
ability as a potential antifungal drug target.
Results
Identification of the GMP Synthase-encoding Gene in
C. neoformans—To begin our characterization of GMP syn-
thase from C. neoformans, the corresponding gene in the type
strain H99 genome was identified via a reciprocal best hit
BLAST analysis employing the S. cerevisiae ortholog GUA1
(45). A single hit was observed, indicating that the gene is
present in single copy. Located on chromosome 11, this
locus was designated as CNAG_018770 in the published H99
genome (47); subsequently employing CNAG_018770 as the
query sequence in a BLAST search of the S. cerevisiae
genome identified GUA1 as the only hit in that species. The
gene CNAG_018770 has therefore been named GUA1 after
the S. cerevisiae ortholog, whose predicted product is 65%
identical at the amino acid level. In comparison, Gua1 is 50%
identical to GuaA in E. coli, 35% identical to human GuaA
isoform 1, 23% identical to the human GuaA, and 23% iden-
tical to human GuaA isoform 2.
Gua1 Is Essential for Guanine Protrophy in C. neoformans—
To verify that the identified gene designated as GUA1 encodes
GMP synthase, we performed a biolistic targeted gene deletion
inC. neoformans type strainH99. Consistent with our bioinfor-
matic predictions, the gua1 strain could not grow on YNB
minimal medium, but growth was restored (albeit incom-
pletely) upon the addition of guanine (Fig. 1B). The gua1
strain was not, however, able to utilize the guanine naturally
present in rich YPD medium, nor was growth restored by the
addition of exogenous guanine to YPD (data not shown); this
unusual phenotype was consistent with that previously
reported for the IMP dehydrogenase imd1mutant (25). Rein-
troducing a wild-type copy of the gene to create strain
gua1GUA1 restored growth onbothYNBandYPDmedium
(Fig. 1B). Together, these data are consistent with GUA1
encoding GMP synthase.
To gain insight into potential growth defects that may be
exhibited during infection independent of guanine starvation,
the effect of deletingGUA1 on the growth rate was investigated
in RPMI 1640 medium supplemented with 1 mM guanine.
Again, even in the presence of guanine, the gua1mutant dis-
played slower growth compared with both wild type and the
complemented gua1GUA1 strain because of an extended
lag phase (Fig. 1C). Furthermore, themutant reached stationary
phase at an optical density lower than the wild-type or comple-
mented strains. The delayed and reduced growth of themutant,
even in the presence of guanine concentrations far exceeding
the limited amounts in mammalian cerebrospinal fluid (0.5
2 The abbreviations used are: XMP, xanthine monophosphate; PDB, Protein
Data Bank; GATase, glutamine amidotransferase; DON, 6-diazo-5-oxo-L-
norleucine; SEC, size exclusion chromatography; MALLS, multiangle laser
light scattering; LB, lysogeny broth; NGM, nematode growthmedium; BHI,
brain-heart infusion; L-DOPA, L-3,4-dihydroxyphenylalanine; AMP-PNP,
adenosine 5-(,-iminotriphosphate).
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M (29)), suggested the mutant was likely to exhibit severe
attenuation or avirulence in infection models.
Loss of GMP Synthase Affects Production of C. neoformans
Virulence Determinants—During the infection process, C. neo-
formans relies on a number of key virulence factors that play an
important role in protecting the pathogen from host defenses,
facilitating dissemination and growth. To observe the effects of
the gua1 mutation on the production of these virulence fac-
tors while limiting the confounding influence of guanine star-
vation influencing growth, in vitro virulence factor production
assays were performed in the presence of exogenous guanine.
The complex polysaccharide capsule protects the fungal cells
against phagocytosis by immune cells during infection. When
grown in guanine-supplemented capsule-inducing RPMI 1640
medium, the gua1mutant produced significantly less capsule
than wild type and the complemented gua1GUA1 strain
after 30 h at both 30 and 37 °C (p 0.0001; Fig. 2A). The viru-
lence factor melanin protects C. neoformans against the effects
of oxidants, such as those produced by phagocytic cells. When
plated on guanine-supplemented L-3,4-dihydroxyphenylala-
nine (L-DOPA) medium, production of melanin was delayed;
this delay was more pronounced at 37 °C. Production of pro-
teases enables C. neoformans to degrade host tissue and facili-
tate dissemination, as well as obtain nutrients for growth. On
guanine-supplemented protease-inducing medium, protease
activity was undetectable in the gua1 mutant at either 30 or
37 °C (Fig. 2). In summary, loss of GMP synthasewas associated
with delayed or abolished production of the known virulence
factors capsule, melanin, and proteases, and this wasmore pro-
nounced at human body temperature, providing further evi-
dence that the gua1 mutant was likely to exhibit impaired
virulence.
GMPSynthase Is Critical for C. neoformans Virulence in Both
Nematode and Murine Models—The compromised growth
rate and virulence factor production of the gua1 mutant
strongly suggested the strain would be unlikely to successfully
cause infection. Evaluation of virulence was first performed in
the nematode Caenorhabditis elegans, a natural predator of
C. neoformans (64). Nematodes were introduced onto a lawn of
wild-type, gua1, or gua1GUA1 cells grown on rich brain-
heart infusion (BHI) medium, minimal nematode growth
medium (NGM), and minimal NGM supplemented with 1 mM
guanine. No difference in virulence was observed between the
wild-type, gua1, and gua1GUA1 strains when grown on
BHI or NGM supplemented with guanine (p  0.1; Fig. 3A).
Given the abundance of guanine in bird guano, this result was
consistent with what could be expected in the environmental
niche whereC. neoformans encounters this predator. However,
on NGM lacking guanine supplementation, the gua1mutant
was avirulent (p 0.0001; Fig. 3A).
The nematode data indicated the importance of GMP syn-
thase for virulence was influenced by the abundance of guanine
available. Given the low concentrations of available purines in
cerebrospinal fluid (28–30), we investigated the effect of gua1
on virulence using amurine inhalationmodel of crypotococco-
sis. Mice infected with the wild-type and gua1GUA1 strains
displayed equivalent progression of disease, succumbing to the
infectionwithin 20 days (Fig. 3B). In contrast, rather than losing
weight and displaying other disease-associated symptoms, all
mice infected with the gua1 strain gained weight and were
healthy until the 60-day end point of the experiment (Fig. 3B).
Furthermore, fungal burden analysis from sacrificed animals
showed the infection had been cleared from all mice infected
with the gua1mutant, similar to previous observations (25).
C. neoformans GMP Synthase Enzyme Kinetics Show Differ-
ences to the Human Ortholog in Binding Cooperativity—Given
the importance of Gua1 during murine infection, we expanded
our analyses to investigate the biochemical function of C. neo-
formans GMP synthase. To identify possible functional differ-
ences between the fungal and human enzymes that could be
exploited in therapeutic agent development, His-taggedC. neo-
formans Gua1 was expressed in E. coli and purified, and the
histidine tag was removed prior to use of recombinant Gua1 in
steady-state kinetic analysis.
The dual catalytic action of GMP synthase is required for the
amination of XMP to GMP and involves two main steps: ini-
tially adenyl-XMP is produced by the ATP pyrophosphatase
(ATP-PPase) domain in the presence ofMg2, and this product
then reacts with ammonia produced by the hydrolysis of gluta-
mine that is catalyzed by theN-terminal glutamine amidotrans-
ferase (GATase) (33, 38). The amination of XMP in C. neofor-
mans GMP synthase protein displayed Michaelis-Menten
kinetics with aKm of 65.9 13.0M and a kcat of 0.4 s	1 for the
overall reaction. ATP adenylation also exhibited Michaelis-
FIGURE1.ThedenovoandsalvagepurinebiosynthesispathwayandGMP
synthase role in GTP biosynthesis. A, IMP dehydrogenase and GMP syn-
thase catalyze the first two steps of the guanylate branch of de novo purine
biosynthesis. B, 10-fold serial dilutions of indicated strains were spotted onto
YNBmedium supplemented with specified purines (1 mM) and incubated for
2 days at 30 °C. C, strains were grown for 6 days in RPMI 1640 medium sup-
plemented with 10% serum and 1 mM guanine at 30 °C, with A600 readings
collected every 12 h.
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Menten kinetics and had a Km of 77.5  6.0 M. In contrast,
kinetic data for Mg2, which is required as a co-factor for the
reaction of XMP to adenyl-XMP, revealed a sigmoidal response
to increases in substrate concentration, which is indicative of
cooperative binding and was best fitted with a Hill coefficient
(n) of 2.2 0.2 and a K0.5 of 1289.0 66.0M. The final part of
the reaction, hydrolysis of glutamine by the GATase domain in
the C. neoformans protein, displayed Michaelis-Menten kinet-
ics and had a Km of 1130.0  162.0 M, showing a low affinity
for this substrate.
Compared with previously identified GMP synthases, the
kinetic parameters of the C. neoformans enzyme were most
similar to those of the Mycobacterium tuberculosis GMP syn-
thase, which was reported to have similar binding affinity. For
XMP, the binding affinity was only moderately lower between
C. neoformans (65.9 13.0M) andM. tuberculosis (45.0 1.0
M) and different between human (35.6 1.8 M) and C. neo-
formans, and unlike M. tuberculosis and human enzymes, the
C. neoformans enzyme did not show cooperative binding of
XMP (58, 59). The Km of ATP is moderately higher than
reported inM. tuberculosis (27 2M) but considerably lower
than human GMP synthase (132 7 M). The affinity for glu-
tamine and Mg2 in C. neoformans GMP synthase was most
like M. tuberculosis (Table 1). However, the magnitude of the
positive cooperativity observed for XMP binding in the human
enzyme was moderate, with a Hill (n) coefficient of 1.48 (59),
whereas M. tuberculosis GMP synthase had a Hill (n) coeffi-
cient of 2.4 (58). Overall, the humanGMP synthase protein had
a significantly higher (12
) turnover number than theC. neo-
formans protein, and the concentration of glutamine required
to reach saturation was almost three times higher forC. neofor-
mans (1130  162 M) compared with human GMP synthase
enzyme (406 49 M) (58, 59), confirming potentially impor-
tant kinetic differences in these enzymes.
ECC1385 Is an Inhibitor of C. neoformans GMP Synthase—
Given the biochemical differences uncovered above and the
importance of GMP synthase in virulence inC. neoformans, we
next investigated the ability to phenocopy the gua1 pheno-
type with a chemical inhibitor. The best known inhibitor of
GMP synthase is 6-diazo-5-oxo-L-norleucine (DON), a well
characterized glutamine agonist that targets several gluta-
mine binding proteins, in particular phosphoribosylformylgly-
FIGURE 2. Loss ofGUA1 compromises virulence factor production. A, C. neoformans strains were incubated in RPMI 1640medium, 10% fetal bovine serum,
and1mMguanineat 30and37 °C.At 30h, the cellswere stainedwith India ink. The relative capsulediameter value shows themean, and the error bars represent
S.E. ****, p 0.0001. B, melanin production was determined on L-DOPA medium with strains incubated at 30 and 37 °C for 48 h. C, protease production was
determined on YNB medium with amino acids and 0.1% bovine serum albumin plates with strains at 30 and 37 °C for 48 h.
FIGURE 3. Virulence of gua1 mutant in nematode and murine host systems. A, Bristol N2 C. elegans were transferred onto lawns of the indicated
C. neoformans strains grown on BHI medium, minimal medium, andminimal medium supplemented with 1 mM guanine and incubated at 28 °C, and survival
wasmonitored. Forminimalmedium, the gua1mutant strain was avirulent, differing from thewild-type or gua1GUA1 strains (p 0.0001). No significant
difference in virulence was found between strains when grown on richmedium orminimal medium supplemented with guanine (p 0.1). B, virulence of the
gua1mutant in the murine inhalation model of infection. 6-week-old female BALB/c mice were infected with H99, gua1, or gua1GUA1 C. neoformans
strains (n 10), and survival wasmonitored over 60 days. Survival of mice with wild-type or gua1GUA1 strains showed no significant difference (p 0.05),
and survival was significantly lower than in those infected with the avirulent gua1 mutant strain (p  0.0001). C and D, posthumous organ burden was
calculated in colony-forming units (CFU)/g of organ as described.
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cinamidine synthetase and CTP synthetase (65–67). In the
context of antimycotic development, however, a nonspecific
inhibitor is of little interest because a number of off target
effects in the host would be anticipated, and so it was deemed
unsuitable for this study. Ones potentially important lead com-
pound was ECC1385, a synthetic compound that showed
potent activity against a number of other fungal pathogens (26).
A genetics-based investigation revealed that ECC1385 had
potency against the GMP synthases from C. albicans and
A. fumigatus and that the compound had a different mode of
action to a glutamine agonist (26).
We tested ECC1385 as a direct inhibitor of purifiedC. neo-
formans GMP synthase using concentrations between 0 and
200 M, which revealed an IC50 of 4.4 M, providing the first
biochemical evidence that ECC1385 acts directly on the
activity of purified GMP synthase. However, subsequent
broth dilution assays to determine the inhibitory action of
ECC1385 against C. neoformans failed to inhibit growth,
despite employing a concentration range reaching 100 M,
far exceeding the potency determined in the enzyme assay.
Importantly, although this compound cannot serve as an
antifungal itself, it provides evidence that the activity of
GMP synthase can be inhibited without depending on a non-
specific agent.
Predicted Differences between Human and C. neoformans
GMP Synthase—The process of rational drug design can be
greatly facilitated by the knowledge of the three-dimensional
structure of the target. To this end, we endeavored to solve the
crystal structure of C. neoformans GMP synthase; however,
despite extensive efforts, we were unable to obtain a protein
structure because of poor crystal quality.
To gain insight into GMP synthase structure in the absence
of a crystal structure, we used size exclusion chromatography
(SEC) coupled with multiangle laser light scattering (MALLS)
to determine the oligomeric state of GMP synthase in solution.
Human GMP synthase is a monomer in solution with a small
dimer population; however, in the active form, when all sub-
strates are bound, there is evidence that it forms a dimer (43). In
contrast, E. coli GMP synthase is a homodimer is solution (39,
68). The elution profile for C. neoformans GMP synthase dem-
onstrates that this protein predominantly forms a dimer (120
kDa) in solution, with a small tetramer population (Fig. 4). The
quaternary structure of C. neoformans GMP synthase is there-
fore more similar to E. coli than the human protein.
To compare potential structural differences between the
human and C. neoformans enzymes, a homology model (63) of
C. neoformans GMP synthase was generated using the E. coli
enzyme as a template; there are no reported fungal GTP syn-
thase structures, and of those species for which a structure has
been determined, the E. coli enzyme exhibited the highest pro-
tein identity (50%) with C. neoformans (34).
Overall, the structural model of C. neoformans, based on the
E. coli structure, has three distinct regions: dimerization, ATP-
PPase, and GATase domains (Fig. 5). The human GMP syn-
thase has been reported to have two distinct groups of its
dimerization domain (D1 and D2) as well as the ATP-PPAse
and GATase domains, and in this respect C. neoformans GMP
synthase is more closely related to E. coli (Fig. 5). Like E. coli,
C. neoformans GMP synthase is a dimer in solution (Fig. 4),
whereas human GMP synthase is a monomer in solution and
believed to dimerize upon substrate binding.
Although lacking two subsections, the dimerization domain
of E. coli and C. neoformans includes most amino acids
required for XMP binding, and the highly conserved dimeriza-
tion subdomain with the consensus sequence Val-Gly-Val-
Xaa-Gly-Asp-Xaa-Arg-Xaa-Tyr (supplemental Fig. S3). This
subdomain is present in the D1 domain of human GMP syn-
thase rather than D2, which has a high level of identity with
C. neoformans and E. coli GMP synthase.
In the human GATase domain, three key residues are
involved in the binding of glutamine: Cys104, His190, and
FIGURE 4. Solution properties of C. neoformansGua1. A, blue lines indicate
the trace from the refractive index detector (arbitrary units) during size exclu-
sion chromatography. Magenta lines indicate the average molecular weight
(y axis) distribution across thepeakbyMALLS. B, SDS-PAGE confirms themass
of a monomer of GMP synthase at60 kDa.
TABLE 1
Comparison of kinetic parameters of GMP synthase from different organisms
The values are shown S.E. ND denotes no data. The assay conditions used were as follows:C. neoformans (Tris buffer, pH 7.5, 0.15mMXMP, 1mMATP, 5mM glutamine,
and 20mMMgCl2),E. coli (60mMHepes buffer, pH8, 0.2mMXMP, 5mMATP, 200mMglutamine, 20mMMgCl2),M. tuberculosis (50mMTris buffer, pH7.5, 0.15mMXMP,
1 mM ATP, 5 mM glutamine, 20 mM MgCl2), P. falciparum (90 mM Tris buffer, pH 8.5, 0.15 mM XMP, 2 mM ATP, 5 mM glutamine, 20 mM MgCl2), and H. sapiens (75 mM
Tris buffer, pH 7.8, 1 mM XMP, 2 mM ATP, 5 mM glutamine, 10 mM MgCl2).
Species Kcat(XMP) Km(XMP) n Km(ATP) Km(Gln) K0.5(Mg2) Reference
s	1 M M M M
C. neoformans 0.41 65.9 13 ND 77.5 6 1130 162 1289 66 This work
E. coli ND 166 43 ND 104 44 ND ND Ref. 35
M. tuberculosis 2.3 45 1a 2.4 27 2 1240 60 1180 30 Ref. 58
P. falciparum 0.43 16.8 2 ND 260 38 472 69 2090 30 Ref. 71
H. sapiensb 5.4 35.6 1.8a 1.48 132 7 406 49 1780 70 Ref. 59
a K0.5 (for substrates where cooperativity was observed) instead of Km.
b A second variant for humans has been reported, but values between the two were catalytically indistinguishable.
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Glu192. These residues form a catalytic triad that is highly
conserved among the amidotransferases, and it is also con-
served in C. neoformans GMP synthase (supplemental Fig. S3),
as well as E. coli (data not shown) (43). The XMP binding site
would be a more viable drug target of GMP synthase given
that glutamate analogs, such as DON, target other enzymes
as well. Of the residues that interact with XMP in human
GMP synthase, one residue, Gln610, was particularly inter-
esting because it is part of the D1 domain that is absent from
C. neoformans GMP synthase (43). Two other residues were
not identified in the model but can be seen in the sequence
alignment as being conserved. Given the large conformation
change believed to occur during XMP amination and the
homology model based on AMP-bound E. coli GMP syn-
thase, the model may not represent the XMP-bound state.
The D2 domain contains other amino acids, which contrib-
ute to XMP binding, and for the most part, these amino acids
are conserved; however, at position Glu694 in the humans
enzyme, C. neoformans GMP synthase has a leucine.
Discussion
C. neoformans GMP synthase was identified based on simi-
larity to the S. cerevisiae ortholog GUA1. The mutant pheno-
type following deletion by biolistic transformation showed that
the enzyme is essential for fungal growth on minimal medium
and required for multiple phenotypes associated with viru-
lence. These virulence factors are key toC. neoformans survival
in the human host; defects in production of melanin, capsule,
and proteases have been demonstrated to cause attenuated vir-
ulence. Furthermore, both capsule andmelanin production are
regulated via a heterotrimeric G protein that requires GTP to
function and, by extension, are dependent on the synthesis of
GTP themselves (69).
Given the auxotrophy and lag observed in the production of
virulence factors, we investigated the importance ofGUA1 dur-
ing infection. Both the nematode and murine models of infec-
tion showed thatGUA1 is essential for virulence, mirroring the
reports for C. albicans and A. fumigatus (26, 44). Furthermore,
in the murine inhalation model, the gua1 strain was com-
pletely cleared by the host immune system.
Together, the in vitro phenotypic assays and the in vivo vir-
ulencemodels show thatGMP synthase could be an useful drug
target. Beyond the obvious requirements for GTP in DNA syn-
thesis, transcription, andenergymetabolism,manycellularpro-
cesses are dependent on regulation via GTP-binding proteins.
Furthermore, the production of the characteristic capsule of
C. neoformans, the pathogen’s most well known virulence fac-
tor, requires GDP-mannose for its biosynthesis (70). Inhibition
of GMP synthase would prevent these key biological processes
and thus be evenmore detrimental toC. neoformans survival in
the hostile host environment.
FIGURE 5. Comparison of GMP synthase fromhuman and C. neoformans in complexwith XMP. A, sequence alignment of human and C. neoformansGMP
synthases prepared using the server ESPript (72). Fuchsia represents XMP, orange represents theGATase domain, green represents theATP-PPase domain, blue
represents theD1domain, and yellow represents theD2 (human) or dimerizationdomain (C. neoformans).Asteriskshighlight residues involved inXMPbinding.
B, the structure of human GMP synthase (PDB code 2VXO), colored as for A. The amino acids responsible for XMP binding are identified as sticks. Asp522 is
contributedby the secondmonomer.C, the structuralmodel ofC. neoformansGMP synthasewasmodeledbasedon theortholog from E. coli.When compared
with the human GMP synthase, C. neoformans does not have Gln610 and shows a single amino acid change at position Leu544, compared with Glu694 in the
human enzyme.
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The biochemistry and the structure of GMP synthase is key
information that could enable the exploitation of this enzyme
as an antifungal drug target, helping address the urgent need for
novel chemotherapeutic agents to combat disseminated myco-
ses. GMP synthase consists of two active sites: one for the bind-
ing of glutamine and the other for XMP and ATP. The homo-
logy model and sequence alignment of C. neoformans GMP
synthase to the human enzyme shows that the catalytic triad
required for glutamine binding is conserved, although kinetic
data showC. neoformansGMP synthase protein to have a lower
affinity for this substrate, maybe because of other residues hin-
dering binding. The best known inhibitor of GMP synthase in
other species is DON, a well characterized glutamine agonist
that targets several glutamine binding proteins. However, given
the lower affinity of the C. neoformans GMP synthase protein
for glutamine as a substrate, it is likely an unsuitable target for
DON-based inhibition and additionally be a nonspecific target
(65–67). In contrast, XMP amination requires interactions
with eight residues in human GMP synthase, of which only five
are homologous to the C. neoformans enzyme. The fact that
the human GMP synthase residue Gln610 is not present in its
fungal homolog, along with residues around the XMP bind-
ing site, may make targeting this site in antifungal develop-
ment worthwhile.
The structural differences betweenGMPsynthase in humans
and C. neoformans identified via homology modeling are con-
sistent with this difference potentially arising from marked
changes in the dimerization domain that contributes key resi-
dues to the humanXMPbinding site as seen in the solvedE. coli
structure. These differences in the binding site of XMP may
enable the development of selective compounds that do not
interact with the human enzyme.
Limited insights into potential starting points for GMP syn-
thase inhibitor development were provided in our study of
ECC1385, which demonstrated potent activity against the puri-
fiedC. neoformansGMPsynthase butwas unable to showactiv-
ity in a whole cell assay. Rodriguez-Suarez et al. (26) demon-
strated whole cell activity against C. albicans in vitro but not in
vivo, instead finding that increased concentrations lead to tox-
icity in the murine model. ECC1385 has specificity toward
GMP synthase; however, it is not adequately active toward
fungi. This could simply be due to an inability to enter the cell.
The mechanism of action of GMP synthase requires all
bound substrates to undergo an intermediate reaction before
coming together to form GMP (34). How this secondary reac-
tion (whereby the adenyl-XMP and GATase domain product
are brought together) occurs is largely unknown, because the
catalytic domains are30 Å apart in the available crystal struc-
tures. To enable GMP synthesis to occur, the enzyme must
either channel the intermediates or undergo a large conforma-
tional change whereby both domains are brought together (34).
It has been suggested that this large conformational change
could be facilitated by the presence of XMP, ATP and Mg2.
When the substrates are bound, the structure likely transitions
into a compact state, creating an ammonia channel that enables
the product of the GATase domain to react with adenyl-XMP
(34, 36). The ability to undergo such a large conformational
change may have contributed to our inability to acquire high
quality diffraction data from our crystallization efforts.
Overall, we have demonstrated that GMP synthase is crucial
for virulence factor production and pathogenesis of C. neofor-
mans in both murine and nematode models. Differences
between human and C. neoformans in enzymatic activity and
amino acids of the XMP binding site make GMP synthase an
attractive antifungal drug target. Historically, the de novo
purine biosynthesis pathway has been a target for many drugs,
in particular against cancer, because they are able to selectively
target the demands of rapidly proliferating cells by starving
them of essential nucleotides. Similarly, disseminating mi-
crobes rapidly proliferate during infection, making this an
attractive target for antibiotics. Given the lack of current drugs
on the market against fungi, novel targets like GMP synthase
are urgently needed.
Experimental Procedures
Bioinformatic Analyses—The C. neoformans type strain H99
genome sequence was reported by Janbon et al. (47). The GMP
synthase-encoding gene was identified in the C. neoformans
genome via reciprocal best hit BLAST analysis querying with
the S. cerevisiae Gua1 protein.
Strains and Medium—C. neoformans strains were cultured
in liquid (1% yeast extract, 2% bacto-peptone, 2% glucose) or
solid (additional 2% agar) YPD medium at 30 °C, and main-
tained at 4 °C for no longer than 2 weeks. gua1mutants were
cultured in liquid YNB (Becton Dickinson) medium supple-
mented with 2% glucose, 10 mM ammonium sulfate, and 1 mM
guanine at 30 °C and maintained at 4 °C on solid YNB (addi-
tional 2% agar) supplemented as before unless otherwise stated.
Cloning and plasmid preparation was performed in E. coli
strain Mach1 (Life Technologies) cultured at 37 °C in lysogeny
broth (LB; 1% tryptone, 0.5% yeast extract, 1% sodium chloride)
supplemented with antibiotics as indicated and maintained on
solid LB (2% agar) supplemented with antibiotics. For virulence
assays, N2 Bristol C. elegans was maintained at 20 °C on NGM
(48) seededwithE. coli strainOP50.Nematode virulence assays
were subsequently performed on BHImedium (Becton Dickin-
son), NGM (48), or NGM supplemented with 1 mM guanine.
Molecular Techniques—The sequences of oligonucleotides
used are listed in supplemental Table S1. The deletion con-
struct for the GUA1 gene was generated using overlap PCR,
employing primers UQ1736 and UQ1739 to join the GUA1 5
region (primers UQ1736 and UQ1737), the G418 resistance
marker NEO (primers UQ234 and UQ235), and the GUA1 3
region (primersUQ1738 andUQ1739). H99 genomicDNAwas
used as the template forGUA1, and the plasmid pJAF1was used
forNEO (49). The deletion construct was transformed into type
strain H99 via biolistic transformation with a Bio-Rad He-1000
Biolistic device (Bio-Rad) with selection onmedium containing
100 g/ml G418 and 1 mM guanine. For complementation,
the GUA1 gene was PCR-amplified (primers UQ1736 and
UQ1739) from H99 genomic DNA, digested with SpeI and
XhoI and cloned into the nourseothricin resistance vector
pCH233 cut with SpeI/XhoI to generate pAK05. The pAK05
GUA1 NAT fragment was subsequently purified as a 6167-bp
SpeI/FspI fragment and transformed into the gua1 mutant,
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selecting for nourseothricin resistance (100 g/ml). For strain
validation, genomic DNAwas prepared using the CTAB proto-
col of Pitkin et al. (50), digested, electrophoresed on TAE-aga-
rose gels, and Southern-blotted onto Hybond-XL membrane
(GE Healthcare, UK) using standard procedures (51). Probes
(primers UQ1736 and UQ1739) were generated using the
Rediprime II kit and [-32P]dCTP (PerkinElmer Life Sciences).
The blots were hybridized at 65 °C, and the membranes were
exposed onto Fuji Super RX medical X-ray film (Fujifilm).
Phenotypic Assays—Production of melanin was assayed on
L-DOPA medium (52) supplemented with 1 mM guanine. Ure-
ase assays were performed on Christensen’s agar (53), and pro-
tease assays were performed on YNB with amino acids and
ammonium sulfate supplemented with 2% glucose, 0.1% BSA,
and 1mM guanine. Images were collected after 24–92 h at 30 or
37 °C. All growth tests were performed in triplicate.
For capsule assays, strains were incubated in RPMI 1640
medium (Life Technologies) supplemented with 2% glucose,
10% fetal bovine serum (Life Technologies), and 1 mM guanine
with shaking at 30 or 37 °C. At 30 h, cells were collected and
stained with India ink (Becton Dickinson) and imaged with a
Leica DM2500 microscope and DFC425C camera. At least 10
independent images were taken, and the relative capsule diam-
eter of 50 cells from each culture was determined as described
by Zaragoza et al. (54). Experiments were performed in biolog-
ical triplicate, and analysis of variance tests were performed in
GraphPad Prism version 7.0 (GraphPad Software) to compare
variation between replicates.
Growth curves were conducted in RPMI 1640 medium sup-
plemented with 2% glucose, 10% fetal bovine serum, and 1 mM
guanine at 30 °C. Starter cultureswere grownovernight, diluted
to A600 0.05, and then monitored spectrophotometrically at
A600 every 12 h for 6 days. Growth curves were performed in
triplicate.
Nematode Virulence Assays—H99, gua1, and gua1GUA1
strains were grown at 30 °C overnight on BHI, minimal
medium, and minimal medium supplemented with 1 mM gua-
nine prior to the introduction of 30–50 synchronized young
adult C. elegans worms and incubation at 28 °C. Worms were
counted every 24 h for 8 days; individuals that did not respond
to touch with a platinum wire pick were considered dead and
removed. Experimental conditions were tested in triplicate,
with Kaplan-Meier survival curves and Mantel-Cox tests per-
formed in GraphPad Prism version 7.0 (GraphPad Software) to
determine significance.
Murine Inhalation Model of Cryptococcosis—For murine
infection assays, 6-week-old female BALB/c mice (Animal
Resources Centre, Murdoch, Australia) were infected by nasal
inhalation (55). For each strain, 10 mice were inoculated with a
50-l drop containing 5
 105C. neoformans cells. Amaximum
of five mice were housed per individually ventilated cage
(Tecniplast) with Bed-o’Cobs 1/8-inch bedding (Andersons),
Crink-l’Nest nesting material (Andersons), and cardboard as
environmental enrichment. The mice were provided rat and
mouse cubes (Specialty Feeds, Glen Forrest, Australia) and
water ad libitum. Eachmousewas examined andweighed twice
daily for the duration of the experiment, with affected mice
euthanized via CO2 inhalation once body weight had decreased
to 80% of preinfection weight or they exhibited symptoms con-
sistent with infection. Death after CO2 inhalation was con-
firmed by pedal reflex prior to dissection. Brain, lungs, liver,
spleen, and kidneys were collected, homogenized in 1ml of PBS
using a TissueLyser II (Qiagen), serially diluted, and plated
on YPD supplemented with 100 g/ml ampicillin, 50 g/ml
kanamycin, and 25 g/ml chloramphenicol (H99 and gua1
GUA1 infectedmice) or YNB supplementedwith 1mMguanine
and antibiotics as before (gua1 infectedmice). The plateswere
incubated at 30 °C, and after 2 days colonies were counted and
used to calculate colony-forming units/g of organ. Kaplan-
Meier survival curves were plotted using GraphPad Prism ver-
sion 7.0 (GraphPad Software). Significance was analyzed using
the log-rank test, whereas organ burden significance was deter-
mined using a one-way analysis of variance with Tukey’s mul-
tiple comparisons test. p values of  0.05 were considered
significant.
Ethics Statement—This study was carried out in strict
accordance with the recommendations in the Australian Code
of Practice for the Care and Use of Animals for Scientific Pur-
poses by the National Health and Medical Research Council.
The protocol was approved by the Molecular Biosciences
Animal Ethics Committee of the University of Queensland
(approval number SCMB/008/11/UQ/NHMRC). Infectionwas
performed under methoxyflurane anesthesia, and all efforts
were made to minimize suffering through adherence to the
Guidelines to Promote the Wellbeing of Animals Used for Sci-
entific Purposes as put forward by the National Health and
Medical Research Council.
Broth Microdilution Assays—Minimum inhibitory concen-
tration susceptibility of C. neoformans to ECC1385 was deter-
mined in accordance with the CLSI M27-A2 guidelines, with
the following modifications: YNB medium supplemented with
ammonium sulfate and 2% glucose, final inoculum concentra-
tion of 1.5–2.0
 103 cells/ml and incubation at 35 °C for 72 h
(25, 56). Drug concentrations ranged from 100M to 49 nM; the
MIC was defined as the concentration that prevented any dis-
cernible growth after 72 h. Fluconazole was employed as a
control.
Expression and Purification of C. neoformans GMP Synthase—
Total RNA was isolated from strain H99 using TRIzol reagent
(Invitrogen), with intron-free cDNA and then synthesized
using a Bioline cDNA synthesis kit (Bioline). The GUA1 ORF
was subsequently PCR-amplified (primers UQ2081 and
UQ2082), and the product was inserted via ligation-indepen-
dent cloning into the SspI site of His tag vector pMCSG7 (57) to
yield pJLC1 and then co-transformed with pLysS into E. coli
strain BL21(DE3) (Merck). Transformed cells were grown at
37 °C in LB supplemented with 100 mg/ml ampicillin and 12.5
mg/ml chloramphenicol to an A600 of 1 then induced with 1
mM isopropyl -D-1-thiogalactopyranoside and grown for a
further 17 h at 22 °C. The cells were harvested and resuspended
in lysis buffer (50 mM HEPES, pH 8.0, 300 mM NaCl, 30 mM
imidazole, 1 mMDTT, and 1mM PMSF) before disruption with
a Sonifier W-450 Digital Ultrasonic Cell Disruptor sonicator
(Branson). Following centrifugation, supernatant was loaded
onto a 5-ml HisTrap Fast Flow column (GE Healthcare) to
purify the histidine tagged protein by immobilized nickel affin-
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ity chromatography. The protein was eluted in a linear gradient
of 30–500 mM imidazole, with a single elution peak. Peak frac-
tions were pooled, concentrated, and incubated overnight with
500 g of tobacco etch virus protease at 4 °C to cleave the
N-terminal histidine tag. Following a second round of nickel
affinity chromatography, GMP synthase was collected from the
flowthrough, concentrated, and further purified using aHiLoad
26/600 Superdex 200 SEC column (GE Healthcare). Protein
was eluted at a rate of 2.5 ml/min with SEC buffer (10 mM
HEPES, pH 7.5, 150mMNaCl, and 1mMDTT) using an A¨KTA-
purifier FPLC system (GE Healthcare). Peak fractions were
combined and concentrated to32 mg/ml and flash frozen in
liquid nitrogen for storage at	80 °C.
Steady-state and Inhibitor Kinetics—GMP synthase activity
was monitored spectrophotometrically using a Cary60 UV-vis-
ible spectrophotometer (Agilent). Assays were carried out as
described for M. tuberculosis by Franco et al. (58) with the
exception of 50mMHEPES, pH7.5, being used instead of 50mM
Tris, pH 7.5; optimized reaction conditions were determined as
0.15 mM XMP, 1 mM ATP, 5 mM glutamine, and 20 mMMgCl2.
The temperature used was 40 °C, consistent with previous
assays conducted for the human, E. coli, and M. tuberculosis
enzymes; this temperature also gave the highest activity in
C. neoformans GMP synthase (35, 58, 59). Purified C. neofor-
mans GMP synthase was used at 0.025 mg/ml final concen-
tration in the assay. Assays were performed in triplicate by
measuring the decrease of absorbance at 290 nm to follow
conversion of XMP (290  4.080 mM	1 cm	1) into GMP
(290 3.066 mM	1 cm	1).  1.014 mM	1 cm	1 was used
to calculate the amount of GMP formed. The data were fitted
to the Hill or Michaelis-Menten equations using Graph-
Pad Prism version 7.0 (GraphPad Software) as appropriate
(Figure S1). The Hill equation was used to calculate the Hill
coefficient (n) (Equation 1) (60). IC50 values were deter-
mined using standard assay conditions with varying concen-
trations of inhibitor ECC1385 (0–100 M) (Figure S2).
 
Vmax[S]
n
K0.5
n [S]n
(Eq. 1)
Multiangle Laser Light Scattering—SEC coupled with
MALLS was performed using a Dawn Heleos II 18 angle light-
scattering detector coupled with an Optilab rEX refractive
index detector (Wyatt Technology). 500 g of GMP synthase
was applied to the HiLoad 26/600 Superdex 200 SEC column at
a flow rate of 0.5 ml/min in 10 mM HEPES, pH 7.5, 150 mM
NaCl, and 1 mM DTT. Molecular mass calculations were per-
formed using Astra 5.3 software (Wyatt Technology). Input of
the refractive increment (dn/dc values) was set at 0.186 in
molecular mass calculations (61).
Crystallization Screens and Modeling of GMP Synthase—
Crystallization experiments of recombinant C. neoformans
GMPsynthasewere performedbyhanging drop vapor diffusion
at 20 °Cwith the commercial sparsematrix screens JCSG,Mor-
pheus, PACT, ProPlex (Molecular Dimensions), INDEX, PEG/
Ion and PEGRx (Hampton Research). Two initial lead condi-
tions (PACT F8, 20% PEG 3350, 0.2 M sodium sulfate
decahydrate, and 0.1 MBis-Tris propane, pH6.5, and PACTG8,
20% PEG 3350, 0.2 M sodium sulfate decahydrate, and 0.1 M
Bis-Tris propane, pH 7.5) were chosen for factorial grid screen
optimization. Despite significant efforts—co-crystallization
with substrates (XMP, AMP-PNP, and MgCl2), streak and
microseeding, enhanced nucleation (62), Silver Bullets (Hamp-
ton Research), and Additive Screen (Molecular Dimension)—
the best resolution diffraction results that could be achieved
using theMX2beamline at theAustralian Synchrotronwas 6Å.
Subsequently we utilized homologymodeling ofC. neoformans
GMP synthase using the automated webserver Modeler (63)
with the E. coli GMP synthase (50% protein identity) structure
as a template (PDB code 1GPM) (34).
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